Article Hero

Europe overwhelmed by the news

1593693544.jpg
Miguel A. Rodriguez
Miguel A. Rodriguez
14 September 2020
Dismal data from Eurostat, but good news from Pfizer.

Over the past two days, the European market received both good and bad news. Somehow, both are related to the novel virus that took over the world.

First, the Eurozone unemployment rate was published today by Eurostat. The rate came in at 7.4% for May, as, at that time, countries started to reopen, and workers were able to return to jobs.  The rate is the worst reading since November 2019, and it means that 12.146 million people were unemployed two months ago. 

The unemployment youth rate with focuses on people between 15-24 years old, increased to 16% from April’s 15.7%. 

However, experts are looking for higher figures, as governments reduced the benefits programs. They have a decade-old example in the last crisis; the unemployment rate was slightly higher than 12%.

Meanwhile, all eyes are on European Central Bank President Christine Lagarde, who is due to speak on Friday, though she already announced that the world should be aware of the second wave of infections, we could be past the worst point of the pandemic. The ECB expects a GDP contraction of 8.7% for the Eurozone for this year, with a 5.2% rebound in 2021.

Second, the markets were moved by positive data received from a COVID-19 potential vaccine developed by Pfizer and BioNTech. It is one of the four potential vaccines that companies are working on. The study showed that the drug created neutralizing antibodies. Pfizer is to manufacture around 100 million doses by the end of the year, and probably more than 1.2 billion by the finish of 2021.

Pfizer stock price gained more than 3% after the announcement. Europe50 gained 1.3% during morning trading. 

Register now and stay updated with the latest market news!

Sources: forexfactory.com, cnbc.com


This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided. 

Share this article

How did you find this article?

Awful
Ok
Great
Awesome

Read More

Miguel A. Rodriguez
Miguel A. Rodriguez
Financial Writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.